Results 21 to 30 of about 39,430 (282)

Complement C5 Inhibitor Ameliorates a Case of Dysferlinopathy. [PDF]

Neurol Neuroimmunol Neuroinflamm
Dysferlinopathy is an autosomal recessive muscular dystrophy caused by pathogenic variants of the DYSF gene. Currently, no clinical effective treatment is available. Given the myopathologic and animal model evidence on complement activation in dysferlinopathy, we explored the potential therapeutic effect of complement inhibition.We reported a case of ...
Kang S, Wang Q, Lv H, Deng J, Zhang W, Lu X, Yuan Y, Wang Z, Zheng F, Yu M.   +9 more
europepmc   +3 more sources

The Role of Complement in Cancer Immunotherapy [PDF]

, 2022
The dual role of complement in both cancer development and treatment has been investigated extensively and is characterized by a substantial literature that documents the conditions in which complement can either enhance tumor growth or promote the ...

core   +1 more source

Sex-Differences and Associations Between Complement Activation and Synovial Vascularization in Patients with Late-Stage Knee Osteoarthritis

Frontiers in Immunology, 2022
PurposeSynovial inflammation in knee osteoarthritis (OA) causes disorganized synovial angiogenesis and complement activation in synovial fluid, but links between complement and synovial microvascular pathology have not been established.
Emily U. Sodhi, Holly T. Philpott, Holly T. Philpott, McKenzie M. Carter, McKenzie M. Carter, Trevor B. Birmingham, Trevor B. Birmingham, C. Thomas Appleton, C. Thomas Appleton, C. Thomas Appleton, C. Thomas Appleton   +10 more
doaj   +1 more source

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Frontiers in Immunology, 2023
IntroductionThe complement system is a key component of the innate immune system, and its aberrant activation underlies the pathophysiology of various diseases.
Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, Michelle D. Hoarty, Rohit Vyasamneni, Douangsone D. Vadysirisack, Zhong Ma, Nanqun Zhu, Jian-Guo Wang, Charlie Bu, Bestine Cong, Elizabeth Palmer, Petra W. Duda, Camil Sayegh, Alonso Ricardo   +14 more
doaj   +1 more source

Terminal Complement Activation Is Induced by Factors Released from Endplate Tissue of Disc Degeneration Patients and Stimulates Expression of Catabolic Enzymes in Annulus Fibrosus Cells

Cells, 2023
Terminal complement complex (TCC) deposition was identified in human degenerated discs. To clarify the role of terminal complement activation in disc degeneration (DD), we investigated respective activating mechanisms and cellular effects in annulus ...
Amelie Kuhn, Jana Riegger, Graciosa Q. Teixeira, Markus Huber-Lang, John D. Lambris, Cornelia Neidlinger-Wilke, Rolf E. Brenner   +6 more
doaj   +1 more source

Complement ratios C3bc/C3 and sC5b-9/C5 do not increase the sensitivity of detecting acute complement activation systemically [PDF]

, 2021
Background Complement activation plays an important pathogenic role in numerous diseases. The ratio between an activation product and its parent protein is suggested to be more sensitive to detect complement activation than the activation product itself.
Nakstad, Espen Rostrup, Bosnes, Vidar, Pischke, Soeren, Andersen, Geir Øystein, Thomas, Anub Mathew, Barratt-Due, Andreas, Chaban, Viktoriia, Orrem, Hilde Lang, Sunde, Kjetil, Lundqvist, Christofer, Seljeflot, Ingebjørg, Schjalm, Camilla, Mollnes, Tom Eirik   +12 more
core   +2 more sources

Recurrent hemolytic uremic syndrome caused by gene mutation: a case report [PDF]

Childhood Kidney Diseases, 2022
Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury without any association with preceding diarrhea.
Baek Sup Shin, Yo Han Ahn, Hee Gyung Kang   +2 more
doaj   +1 more source

Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy

Biomedicines, 2022
The complement system plays a key role in myasthenia gravis (MG). Anti-complement drugs are emerging as effective therapies to treat anti-acetylcholine receptor (AChR) antibody-positive MG patients, though their usage is still limited by the high costs ...
Nicola Iacomino, Fiammetta Vanoli, Rita Frangiamore, Marta Ballardini, Letizia Scandiffio, Federica Bortone, Francesca Andreetta, Fulvio Baggi, Pia Bernasconi, Carlo Antozzi, Paola Cavalcante, Renato Mantegazza   +11 more
doaj   +1 more source

Complement C5 Mediates Experimental Tubulointerstitial Fibrosis [PDF]

Journal of the American Society of Nephrology, 2007
Renal fibrosis is the final common pathway of most progressive renal diseases. C5 was recently identified as a risk factor for liver fibrosis. This study investigated the role of C5 in the development of renal tubulointerstitial fibrosis by (1) induction of renal fibrosis in wild-type and C5(-/-) mice by unilateral ureteral ligation (UUO) and (2 ...
Peter, Boor, Andrzej, Konieczny, Luigi, Villa, Anna-Lisa, Schult, Eva, Bücher, Song, Rong, Uta, Kunter, Claudia R C, van Roeyen, Thomas, Polakowski, Heiko, Hawlisch, Sonja, Hillebrandt, Frank, Lammert, Frank, Eitner, Jürgen, Floege, Tammo, Ostendorf   +14 more
openaire   +3 more sources

Complement Component 5 (C5) Deficiency Improves Cognitive Outcome After Traumatic Brain Injury and Enhances Treatment Effects of Complement Inhibitors C1-Inh and CR2-Crry in a Mouse Model

Neurotrauma Reports, 2023
A potent effector of innate immunity, the complement system contributes significantly to the pathophysiology of traumatic brain injury (TBI). This study investigated the role of the complement cascade in neurobehavioral outcomes and neuropathology after ...
Min Chen, Stephen R. Edwards, Dhiraj Maskey, Trent M. Woodruff, Stephen Tomlinson, David Reutens   +5 more
doaj   +1 more source